Evidence map›Paper›PMID 33116437›Full record

ArticlePatient preference and adherence2020

Group-Based Trajectory Modeling to Identify Patterns of Adherence and Its Predictors Among Older Adults on Angiotensin-Converting Enzyme Inhibitors (ACEIs)/Angiotensin Receptor Blockers (ARBs).

Rutugandha Paranjpe, Michael L Johnson, Ekere J Essien, Jamie C Barner, Omar Serna, Esteban Gallardo, Zahra Majd, Marc L Fleming, Nancy Ordonez, Marcia M Holstad and 1 more

Abstract read
In one paragraph

Article in Patient preference and adherence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rutugandha ParanjpePharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA.
Michael L JohnsonPharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA.
Ekere J EssienPharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA.ORCID 0000-0001-8157-8290
Jamie C BarnerHealth Outcomes Division, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-6078-8093
Omar SernaCareAllies, Houston, TX, USA.
Esteban GallardoCareAllies, Houston, TX, USA.
Zahra MajdPharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA.
Marc L FlemingDepartment of Pharmacotherapy, University of North Texas Health Science Center, Fort Worth, TX, USA.ORCID 0000-0003-0575-7988
Nancy OrdonezPharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA.
Marcia M HolstadNell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, USA.ORCID 0000-0002-5558-8660
Susan M AbughoshPharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA.

Funding

A motivational interviewing intervention customized by patient adherence patternsR15HL135700 · NHLBI · UNIVERSITY OF HOUSTON · PI ABUGHOSH, SUSAN M · 2018 to 2018
$459k
NHLBI NIH HHS R15 HL135700
6 · The paper itself

Abstract

purposeCommonly prescribed medications among patients with comorbid diabetes mellitus and hypertension include ARBs and ACEIs. However, these medications are associated with suboptimal adherence leading to inadequately controlled blood pressure. Unlike traditional single estimates of proportion of days covered (PDC), group-based trajectory modeling (GBTM) can graphically display the dynamic nature of adherence. The objective of this study was to evaluate adherence using GBTMs among patients prescribed ACEI/ARBs and identify predictors associated with each adherence trajectory. PATIENTS AND

methodsPatients with an ACEI/ARBs prescription were identified between July 2017 and December 2017 using a Medicare Advantage dataset. PDC was used to measure monthly patient adherence during the one-year follow-up period. The monthly PDC was added to a logistic group-based trajectory model to provide distinct patterns of adherence. Further, a multinomial logistic regression was conducted to determine predictors of each identified adherence trajectory. Predictors included various socio-demographic and clinical patient characteristics.

resultsA total of 22,774 patients were included in the analysis and categorized into 4 distinct adherence trajectories: rapid decline (12.6%); adherent (58.5%); gaps in adherence (12.2%), and gradual decline (16.6%). Significant predictors associated with all lower adherence trajectories included 90 days refill, >2 number of other medications, ≥1 hospitalizations, and prevalent users. Significant predictors associated with the rapid decline trajectory included male sex, comorbidities, and increased CMS risk score. Further, significant predictors associated with the gaps in adherence trajectory included increasing age, and comorbidities. Lastly, significant predictors associated with the gradual decline trajectory included increasing age, no health plan subsidy, comorbidities, and increasing CMS risk score.

conclusionIdentifying various patient characteristics associated with non-adherent trajectories can guide the development of tailored interventions to enhance adherence to ACEI/ARBs.

Indexed as

adherenceangiotensin converting enzyme inhibitorsangiotensin receptor blockerspredictorstrajectory modeling

Identifiers

PMID33116437
PMCPMC7568634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.